Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0040425 (tonsillitis)
 1,594 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The efficacy of cefpodoxime proxetil has been studied in ten clinical trials conducted in adults suffering from lower respiratory tract infections (pneumonia, acute bronchitis or acute on chronic bronchitis) and upper respiratory tract infections (tonsillitis/pharyngitis or sinusitis). All the trials were controlled, randomized, multicentre and international and seven were double-blind, double-dummy designed. Over a period of 18 months from July 1988 to December 1989, 2448 patients were included. Among them, 2429 (99%) were evaluated for tolerance, 2101 (86%) for tolerance and clinical efficacy and 1018 (42%) for tolerance and clinical and bacteriological efficacy. The clinical response was judged satisfactory in 1205/1263 (95.4%) patients treated with cefpodoxime proxetil and in 788/838 (94%) patients treated with comparative antibiotics. The bacteriological response was judged satisfactory for 662/699 (95%) pathogens for cefpodoxime proxetil treatment versus 427/463 (92, 2%) for comparators. Cefpodoxime proxetil has been given to 7351 patients in the course of its international development with no severe side-effect being observed. Common reactions have been noted with a similar frequency to that seen with the other beta-lactams. No pseudomembranous colitis has been observed during clinical trials. On this basis, cefpodoxime proxetil appears to be efficacious and well tolerated and could be an antibiotic of first choice in the treatment of lower and upper respiratory tract infections in adults and adolescents.
 ...
PMID:Cefpodoxime proxetil: dosage, efficacy and tolerance in adults suffering from respiratory tract infections. 229 35

Two developments of major importance followed Pasteur's discovery of anaerobiosis: Lister revolutionized surgery by recognizing the importance of Pasteur's germ theory of disease and by introducing the antiseptic surgical method. The day of the anaerobe hunter had dawned. The discovery of many anaerobic bacteria linked etiologically to human disease followed, so that by 1900 most of the pathogenic anaerobes were recognized. The frequent occurrence of anaerobic bacterial intoxications, during the two World Wars stimulated the study of clostridia, organisms that dominated the study of anaerobes until the 1960s. During the next decade the emphasis shifted to the non-spore-forming anaerobes due to the work of Finegold in Los Angeles, and Moore and Holdeman in Virginia. Their pioneer studies initiated and carried forward the "anaerobe revolution," and exerted an influence that transformed the clinical and microbiologic approach to anaerobic bacterial infections in almost every field of medical practice. In considering the question, "Where do we go from here?" the author discusses some aspects of anaerobic infections that remain areas of debate or provide pathways for future exploration. Reference is made to the acceptable "anaerobic specimen," and to the problem of "mixed infections." Pseudomembranous colitis is noted and the role of anaerobes in tonsillitis and pharyngitis, bronchitis, and nonspecific vaginitis (vaginosis) is discussed.
 ...
PMID:Anaerobic bacterial diseases now and then: where do we go from here? 637 35